Items where Author is "Kesselheim, Aaron S."

Wouters, Olivier J. ORCID: 0000-0002-2514-476X, Kesselheim, Aaron S., Kuha, Jouni ORCID: 0000-0002-1156-8465 and Luyten, Jeroen (2024) Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014: a retrospective study. Value in Health, 27 (10). 1373 - 1381. ISSN 1098-3015

Wouters, Olivier J. ORCID: 0000-0002-2514-476X and Kesselheim, Aaron S. (2024) Quantifying research and development expenditures in the drug industry. JAMA network open, 7 (6). ISSN 2574-3805

Naci, Huseyin ORCID: 0000-0002-7192-5751, Forrest, Robin, Zhai, Mike, Stofesky, Amanda R. and Kesselheim, Aaron S. (2023) Characteristics of prior authorization policies for new drugs in Medicare Part D. JAMA Health Forum, 4 (2). ISSN 2689-0186

Feldman, William B., Tu, S. Sean, Alhiary, Rasha, Kesselheim, Aaron S. and Wouters, Olivier J. ORCID: 0000-0002-2514-476X (2023) Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. JAMA, 329 (1). 87 - 89. ISSN 0098-7484

Cherla, Avi, Mossialos, Elias ORCID: 0000-0001-8664-9297, Salcher-Konrad, Maximilian ORCID: 0000-0002-5628-5266, Kesselheim, Aaron S. and Naci, Huseyin ORCID: 0000-0002-7192-5751 (2022) Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. Clinical Pharmacology and Therapeutics, 112 (4). 846 - 852. ISSN 0009-9236

Naci, Huseyin ORCID: 0000-0002-7192-5751, Kyriopoulos, Ilias-Ioannis ORCID: 0000-0002-3932-8228, Feldman, William B., Hwang, Thomas J., Kesselheim, Aaron S. and Chandra, Amitabh (2022) Coverage of new drugs in Medicare Part D. Milbank Quarterly, 100 (2). 562 - 588. ISSN 0887-378X

Vokinger, Kerstin N., Hwang, Thomas J., Carl, David L., Laube, Yannic, Ludwig, Wolf Dieter, Naci, Huseyin ORCID: 0000-0002-7192-5751 and Kesselheim, Aaron S. (2022) Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. The Lancet Oncology, 23 (4). 514 - 520. ISSN 1470-2045

Cherla, Avi, Naci, Huseyin ORCID: 0000-0002-7192-5751, Kesselheim, Aaron S., Gyawali, Bishal and Mossialos, Elias ORCID: 0000-0001-8664-9297 (2021) Assessment of coverage in England of cancer drugs qualifying for US food and drug administration accelerated approval. JAMA Internal Medicine, 181 (4). 490 - 498. ISSN 2168-6106

Naci, Huseyin ORCID: 0000-0002-7192-5751, Kesselheim, Aaron S., Rttingen, John Arne, Salanti, Georgia, Vandvik, Per O. and Cipriani, Andrea (2020) Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. The BMJ, 371. ISSN 0959-8146

Vreman, Rick A., Naci, Huseyin ORCID: 0000-0002-7192-5751, Goettsch, Wim G., Mantel-Teeuwisse, Aukje K., Schneeweiss, Sebastian G., Leufkens, Hubert G.M. and Kesselheim, Aaron S. (2020) Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 108 (2). pp. 350-357. ISSN 0009-9236

Naci, Huseyin ORCID: 0000-0002-7192-5751 and Kesselheim, Aaron S. (2020) Specialty drugs: a distinctly American phenomenon. New England Journal of Medicine, 382 (23). 2179 - 2181. ISSN 0028-4793

Naci, Huseyin ORCID: 0000-0002-7192-5751, Salcher-Konrad, Maximilian ORCID: 0000-0002-5628-5266, Kesselheim, Aaron S., Dr.rer.nat, Beate Wiesler, Rochaix, Lise, Redberg, Rita, Salanti, Georgia, Jackson, Emily, Garner, Sarah, Stroup, Scott and Cipriani, Andrea (2020) Generating comparative evidence on new drugs and devices before approval. The Lancet, 395 (10228). 986 - 997. ISSN 0140-6736

Naci, Huseyin ORCID: 0000-0002-7192-5751, Smalley, Katelyn R. and Kesselheim, Aaron S. (2017) Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration. JAMA, 318 (7). pp. 626-636. ISSN 0098-7484